TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 12 hour Area Under the Curve (AUC) of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Xerostomia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hypocalcaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall Summary of the Number of Participants With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Technical success in deployment and placement of endoluminal graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection Rates for All Polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with plasma HIV-1 RNA < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline of the microbial gut populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline of the microbial inflammatory uremic toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline of the markers of cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline of the markers of intestinal barrier permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of infections leading to hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Composite criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in fasting hepatic venous pressure gradient (HVPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of composite satisfaction score (CSS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ascites volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discontinuation from study formula due to intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers of Influenza Antibodies for Subjects 6-35 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participants Achieving Seroconversion Against Antigens for Subjects 6-35 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers of Antibodies for Subjects ≥ 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Achieving Seroconversion Against Antigens for Subjects ≥ 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functionality of the affected upper member
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: survival to hospital discharge or 30d survival of OHCA
Endpoint domain: Mortality/survival
Primary endpoint: survival to hospital discharge or 30d survival of IHCA
Endpoint domain: Mortality/survival
Primary endpoint: prevalence of favorable neurological outcome after cardiac arrest according to Cerebral Performance Category (CPC) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: FDOPA uptake rate constant (K(i))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Major Adverse Cardiovascular Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving Virologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified intubation difficulty scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of empiric antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anal fissure pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal fissure healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects at the time of infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Infections after infusion of MSC
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of sequencing assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Validation of the French version of the LARS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of >20% of FVC postnebulization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of >20% of FEV1 postnebulization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Error in arterial blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall incidence of venous thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Coefficient of Variation of Follicular Sizes on Stimulation Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up visit rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ability to adhere to protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of episodes of Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients who tolerate statin at the initial dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients remaining on statin therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in myalgia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular disease incidence
Endpoint domain: Mortality/survival
Primary endpoint: Coronary heart disease incidence
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients alive at pre-specified time points
Endpoint domain: Mortality/survival
Primary endpoint: Best overall response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose (MTD) of TG-0054
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of up-to-date preventive health services delivered per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients completing offline construction of activation maps
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients experiencing device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of adverse events and/or abnormal laboratory values Grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scores (VAS) remain 3 or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of absorption (TINS-50%-early)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total narcotic use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Absorbed dose delivered to prostate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Treatment-Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve 0-t (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0-infinite (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half Life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge on Postoperative Day #2
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: IGF1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of Mesenchymal stem cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: blood ion levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Multidrug resistance (ESBL production)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cardiac Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and Tolerability of MK7009
Endpoint domain: Adverse events/effects
Primary endpoint: Antiviral Activity of MK7009
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in MR grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of primary adverse events (PAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: antiretroviral treatment efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Bulbar Conjunctival Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of days with pain/discomfort
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Lower verbal memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Surface Discomfort Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline - PTSD Checklist for DSM-5 (PCL-5) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression severity as measured by the HAM-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: status of asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wisconsin Upper Respiratory Symptom Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Discontinued Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Women Still Pregnant by Day 7
Endpoint domain: Mortality/survival
Primary endpoint: Expression of survivin in renal tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increment of PGD2 synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trust in eHealth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: E-health usability
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Postoperative pain measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of perioperative hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal endothelium cell change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory and clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Erythematotelangiectatic Rosacea Signs: Redness (Non Transient Erythema)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of Erythematotelangiectatic Rosacea Signs: Telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of Erythematotelangiectatic Rosacea Symptoms: Self-Reported Presence of Flushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MSM Stigma in Syphilis Testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIV Stigma in Syphilis Testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intersectional Stigma in Syphilis Testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MSM Stigma in Diagnostic Effort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIV Stigma in Diagnostic Effort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intersectional Stigma in Diagnostic Effort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evidence of residual block (train of four <0.9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Visual quality of the eye after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 or Higher Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose-limiting Toxicity Incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Who Have Any Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Coefficient of correlation between derecruitment percentage and response to prone position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium assessed by CAM- ICU scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Withdrawal syndrome at dexmedetomidine discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Time Elapsed From First Clamp to Beginning of Wound Dressing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of total venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of total bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in seated diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in vitamin D level in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serotonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total serum testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of Cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Temperature Fluctuations in Maintenance Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Rewarming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of gender-based violence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants reporting anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants reporting minor psychiatric disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of successfully identified reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose for further studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP (serum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain/discomfort (self-assessment from 1 - 10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Evidence of withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate in Patients With EGFR Mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effect on anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of serious Adverse Drug Reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major (serious) hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion of gene signature state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to clinical dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grades I-IV Acute Graft Versus Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic Graft Versus Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: rHuEPO Serum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Quality of Life questionnaire global scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Abnormal Magnetoencephalography (MEG) Slow-Waves (1-4 Hz) Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rivermead Post Concussion Symptom Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neurobehavioral Symptoms Inventory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of clinically overt thromboses or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of occurrence of major and clinically relevant non-major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Event Rate of Major and Non-major Clinically Relevant Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variation of amplitude of the N2P2 cerebral wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulse transit time (PuTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet aggregation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of De-Novo treatment formula
Endpoint domain: Adverse events/effects
Primary endpoint: Acute change in neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute change in convergence function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute change in brain-derived blood biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD4+ T-cell Apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in appetite using Haber Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in appetite using VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Ferritin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma HO-1 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma IL-10 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: level of serum IGF-1 and IGFBP-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum AUC of Tigecycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compliance with inhaler use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects with plasma HIV-1 RNA below the limit of detection (<50 copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with SAEs and proportion with AEs leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in STAI-6 Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline of the number of participants with treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serial PK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Confirmed stent failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and tolerability of VPA
Endpoint domain: Adverse events/effects
Primary endpoint: overall diagnostic accuracy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of clinical screening program
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline frailty score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Patients With PSA Decline by 50% From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes